[HTML][HTML] 晚期非小细胞肺癌EGFR-TP53 共突变的研究进展
王蓉， 潘思思， 宋霞 - Chinese Journal of Lung Cancer, 2022 - ncbi.nlm.nih.gov
随着二代基因检测（ next generation sequencing, NGS） 技术的快速发展及广泛应用，
多种共突变基因被我们发现。 许多研究表明， 共突变在表皮生长因子受体（ epidermal growth …
多种共突变基因被我们发现。 许多研究表明， 共突变在表皮生长因子受体（ epidermal growth …
Apatinib enhances chemosensitivity of ABT‐199 in diffuse large B‐cell lymphoma
Y Shi, J Ye, H Shen, Y Xu, R Wan, X Ye… - Molecular …, 2022 - Wiley Online Library
To investigate the effect of Apatinib (an inhibitor targeting VEGFR‐2) enhances
chemosensitivity of ABT‐199 on diffuse large B‐cell lymphoma (DLBCL). Viability assay and …
chemosensitivity of ABT‐199 on diffuse large B‐cell lymphoma (DLBCL). Viability assay and …
Comparison of the Efficacy of EGFR‐TKIs Combined with Antiangiogenic Agents between Patients with Exon 19 Deletion and Patients with Exon 21 Leu858 Arg …
XB Pan, FS Liang, QY Tang, HW Liang… - Journal of …, 2022 - Wiley Online Library
Purpose. To compare the efficacy of EGFR‐TKIs combined with antiangiogenic agents
between non‐small cell lung cancer patients with exon 19 deletion and patients with exon …
between non‐small cell lung cancer patients with exon 19 deletion and patients with exon …
表皮生长因子受体阳性非小细胞肺癌脑转移患者靶向联合治疗研究进展
王亚静， 段晓阳， 侯冉， 黄娅婕， 史健 - 中国全科医学 - chinagp.net
脑转移是非小细胞肺癌(NSCLC) 患者预后不良的主要因素. 在表皮生长因子受体(EGFR)
突变的NSCLC 患者中脑转移的发生率更高, 针对此靶点的酪氨酸激酶抑制剂(EGFR-TKI) …
突变的NSCLC 患者中脑转移的发生率更高, 针对此靶点的酪氨酸激酶抑制剂(EGFR-TKI) …
Clinicopathologic and Molecular Subtyping of EGFR Mutation—Response
HA Jung, J Lim, YL Choi, J Kim, K Park - Clinical Cancer Research, 2023 - AACR
We appreciate the comments from S. Sorscher regarding our recently published
article,“Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage …
article,“Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage …
Evaluation of Apatinib‐Related Hypertension and Identification of Clinical Risk Factors
K Le, M Liu, Y Ma, J Yan, Y Li… - Journal of Clinical …, 2024 - Wiley Online Library
Purpose. Hypertension (HTN) is one of the most common adverse drug reactions to tyrosine
kinase inhibitors (TKIs) targeting vascular endothelial growth factor (VEGF), but little is …
kinase inhibitors (TKIs) targeting vascular endothelial growth factor (VEGF), but little is …
[HTML][HTML] 甲状腺未分化癌靶向治疗研究进展
Q Chenhong, L JIANG, XU Shiying… - Journal of Zhejiang …, 2021 - ncbi.nlm.nih.gov
甲状腺未分化癌（ ATC） 是一种恶性程度高、 侵袭性强的甲状腺恶性肿瘤， 发病迅速， 预后差，
目前尚缺乏有效治疗手段。 分子靶向治疗为ATC 治疗提供了一种新思路 …
目前尚缺乏有效治疗手段。 分子靶向治疗为ATC 治疗提供了一种新思路 …
Clinical efficacy of Apatinib combined with Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in nonsmall cell lung cancer after EGFR-TKI …
R Tian, Y Guo, X Zhang, X Zhang, X Song - Pakistan Journal of Medical …, 2024 - pjms.org.pk
Objective: To evaluate the efficacy and safety of Apatinib combined with epidermal growth
factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in the treatment of patients with non …
factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in the treatment of patients with non …
[HTML][HTML] The efficacy and safety of apatinib in patients with heavily pretreated end-stage cancer: a retrospective study
Z Li, X Zhou, S Wang, L Shi, R Meng, X Dai… - Translational Cancer …, 2023 - ncbi.nlm.nih.gov
Background Anti-angiogenesis therapy has been a vital treatment option in a variety of
cancers. Assessing the efficacy and safety of apatinib in patients with heavily pretreated end …
cancers. Assessing the efficacy and safety of apatinib in patients with heavily pretreated end …
[HTML][HTML] Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory …
Background Ramucirumab plus erlotinib (RAM+ ERL) demonstrated superior progression-
free survival (PFS) over placebo+ ERL (PBO+ ERL) in the phase III RELAY study of patients …
free survival (PFS) over placebo+ ERL (PBO+ ERL) in the phase III RELAY study of patients …